Intrathecal trastuzumab in the management of HER2+ breast leptomeningeal disease: a single institution experience

ConclusionsIT trastuzumab was well tolerated with prolongation of OS over historical controls. IT trastuzumab should be considered for management of HER2+ leptomeningeal disease patients.

Source: Breast Cancer Research and Treatment - February 1, 2018 Category: Cancer & Oncology Source Type: research